A small reflection on the current reality! Although THRM remains at the forefront of the field, further news will be required to confirm the approval and then the awarding of contracts. Patience is required for sure, but we must not forget that more and more players are being approved. THRM must therefore announce its product and get it approved quickly in order to keep a major part of the market. It takes a certain amount of time for people to adopt a product, which is why it must be introduced more quickly. On the other hand, there are so many unknowns as a result of COVID-19 that the need for testing could extend over years and never disappear. To be at the forefront as THRM is can only make us happy. A mass-distributed, home-based saliva test meets people's demand very well and would cover a large part of the population providing huge revenues and a profit margin on contracts of up to 50%. The sooner we have the product and its characteristics, the sooner we will be able to deduce what will become of THRM's share value.